Refractive surgeons should be aware of the possibility that a surgical marker pen (Codman; Johnson & Johnson) could be a cause of diffuse lamellar keratitis (DLK) after LASIK, said Wei-Han Chua, MD.
Refractive surgeons should be aware of the possibility that a surgical marker pen (Codman; Johnson & Johnson) could be a cause of diffuse lamellar keratitis (DLK) after LASIK, said Wei-Han Chua, MD.
Dr Chua reported on a cluster of nine cases of DLK that occurred at the Singapore National Eye Centre. All eyes had undergone LASIK or flap relift/repositioning on a single day (July 24, 2007) and DLK of varying grades was noted on the first postoperative day.
To investigate the outbreak, a review was undertaken of all LASIK procedures performed over the four-day period from July 23 to 26, 2007. DLK occurred in nine of 12 eyes that had surgery on July 24th with use of the surgical marker pen and in none of 113 eyes operated on during the other three days when a surgical marker pen from another manufacturer was used to ink the corneal marker. Dr Chua postulated that one or more of the constituents of the ink in the surgical marker pen in question might have incited the inflammatory response.
"It can be difficult to identify risk factors or causative agents in DLK, even when outbreaks occur. However, because of the use of strict protocols for recording the introduction of all new equipment and consumables used for LASIK procedures, we could determine that the introduction of a new brand of surgical markers was the only change made to the surgical regimen on the day the DLK eyes had their procedures," Dr Chua said.
"To our knowledge, this is the first report of DLK associated with a surgical marker. After we communicated our experience, the manufacturer replied that the surgical marker is intended for use only on the skin and is not meant to be used on the eyes," he concluded.
Read
ASCRS 2008 meeting highlights.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.